Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

NCT00049192 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

NIH

Sponsor class

Conditions

Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia
Relapsing Chronic Myelogenous Leukemia

Interventions

BIOLOGICAL: oblimersen sodium
DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)